Maxime Ranger
@max_ranger
1 love, dad of 2 wonderful kids. PhD MBA | Scuba Diver | Activator Achiever | Cofounder Inversago, CEO Neurenati & Numbio Thera | Opinions are my own
You might like
Thank you François Ravenelle for your exceptional leadership of @inversago. Welcome, Micheline Beauvais, as you write an exciting new chapter with us as our new CEO. inversago.com
Newborns with Hirschsprung's disease deserve a treatment option to avoid surgery. Preclinical efficacy data showed that NEU-001 hold promise in regenerating the enteric nervous system of these children. Looking forward to supporting Neurenati in its... businesswire.com/news/home/2024…
The financial support from Impulsion PME will first allow the development of an optimal formulation for this curative treatment and to move quickly towards clinical trials businesswire.com/news/home/2024…
La performance de Charlotte Cardin au Match des étoiles de la NBA.
Presentation of Betsabeh MandariHermann, Global Head of Research, Philips @espacecdpq @MEDTEQ_CA Sectoral Asset Management
Journée carrière à Externat Sacré-Coeur, l’école de ma fille. Je vais essayer de leur expliquer ce que je fais…. Ichhh je vais juste les mêler ;) ça va être fun
C'est vendredi, on fait l'amour. *Mais faut se laver les fesses avant!
🚨 "Les femmes de gauche sont parmi les femmes les plus laides que j'ai jamais vu" Brian Glenn est le journaliste qui, sur RSBN, accompagne tous les meetings de Trump. Quelques minutes avant l'arrivée du candidat en Iowa, il a donné son avis sur les femmes de gauche : "Les…
Sommes à la Ronde. C’est vide! Aucune attente, jamais vu cela débile. Les boyz adorent le Titan….
Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with @giiant_pharma for Multiple Oral Drug Candidates Targeting #InflammatoryBowelDisease. bit.ly/3r3cLAs $PALI #UlcerativeColitis #ChronsDisease #IBD
Finally… FDA approves Ipsen’s palovarotene for ultra-rare disease – Endpoints News endpts.com/fda-approves-i…
The Inversago Pharma Origin Story - from Creation to Exit
Genesys portfolios company Veralox Therapeutics strides forward with the appointment of seasoned executive Jonathan Mow as the CEO and announces closing of $24M financing to initiate its Ph2 HIT trial finance.yahoo.com/news/veralox-n…
finance.yahoo.com
Veralox Names Jonathan Mow as Chief Executive Officer as the Company Advances Development of...
-- New Financing of $24 Million Fully Funds the Phase 2 Clinical Program for Lead Candidate VLX-1005 -- Company Prepares to Evaluate VLX-1005 in Heparin-Induced Thrombocytopenia (HIT) FREDERICK, Md.,...
United States Trends
- 1. Thanksgiving 363K posts
- 2. Fani Willis 4,880 posts
- 3. Trumplican 1,941 posts
- 4. Golesh 1,134 posts
- 5. Hong Kong 70K posts
- 6. #wednesdaymotivation 6,046 posts
- 7. #Wednesdayvibe 3,171 posts
- 8. Mora 22.7K posts
- 9. Ruth 14.1K posts
- 10. Gretzky N/A
- 11. Good Wednesday 34.4K posts
- 12. Elijah Moore N/A
- 13. Nuns 9,561 posts
- 14. Karoline Leavitt 27.7K posts
- 15. #puebloenbatallayvictoria 2,928 posts
- 16. Ribs 11.6K posts
- 17. stranger things 151K posts
- 18. Khabib 4,806 posts
- 19. BYOB N/A
- 20. #BurnoutSyndromeSeriesEP1 254K posts
Something went wrong.
Something went wrong.